While the titans of the Chinese internet—Tencent’s Pony Ma and ByteDance’s Liang Rubo—are locked in a high-decibel war over AI subsidies and user acquisition, Baidu’s Robin Li has adopted a posture of strategic quietude. Behind this silence, however, lies an aggressive financial gambit. In the first quarter of 2026, Baidu has moved to spin off three of its most significant assets—AI chipmaker Kunlun Xi, biotech venture BioMap, and streaming giant iQIYI—for confidential initial public offerings in Hong Kong. This collective monetization represents a watershed moment for Baidu’s long-standing 'All in AI' strategy.
Yet, the timing of this IPO spree is fraught with contradiction. Since the beginning of 2026, Baidu’s own market capitalization has eroded by roughly 32%, with its valuation sliding from 440 billion HKD to under 300 billion HKD. This divergence highlights a persistent tension: while Baidu is successfully maturing its internal AI projects into independent entities, the broader capital market remains deeply skeptical of whether these assets can actually sustain the parent company’s future growth.
Kunlun Xi serves as the hardware cornerstone of this portfolio. Originally an internal department, it has matured into a formidable player in China’s domestic procurement market, recently securing major contracts with China Mobile and China Merchants Bank. Despite generating over 1 billion RMB in revenue in 2024 and eyeing explosive growth by 2026, its current valuation of 21 billion RMB lags significantly behind peers like Moore Threads. This 'Baidu discount' suggests that investors view Kunlun as a specialized inference tool rather than a general-purpose GPU powerhouse with infinite scalability.
In the realm of life sciences, BioMap represents Li’s personal ambition to bridge AI and biology. Chaired by Li himself, the company boasts one of the world’s largest foundational models for life sciences, xTrimo V4. While it has secured a billion-dollar partnership with Sanofi, it faces a cooling global appetite for AI drug discovery. For BioMap to succeed in its IPO, it must prove it can transition from a research-heavy incubator to a commercially viable entity at a time when biotech valuations are being ruthlessly scrutinized.
iQIYI presents a different set of challenges. Once the darling of Chinese streaming, its narrative has shifted from growth to survival. Despite aggressive claims of AI-driven cost reductions, the platform’s 2025 revenue and net profit have both trended downward. Its return to the Hong Kong market is less about AI prestige and more about securing a liquidity lifeline as its cash reserves dwindle. For investors, iQIYI is a litmus test for whether AI can truly save a legacy content business from structural decline.
Historically, Baidu has been lauded as the 'Whampoa Military Academy' of Chinese AI, a title that is both a badge of honor and a structural curse. While it has incubated the talent that now leads China’s autonomous driving and LLM sectors, it has struggled to retain that human capital. The recent exodus of over 14 vice-president-level executives underscores a persistent brain drain. As these three subsidiaries head to market, the ultimate question is whether they can thrive as independent actors or if they will remain perpetually hampered by their identity as Baidu appendages.